Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The optimal duration of alendronate treatment is an important issue. In the FLEX study by Dr Black and colleagues,1 1099 women previously enrolled in the FIT trial who completed 5 years of alendronate were randomized to continue alendronate or to receive placebo for another 5 years. The overall fracture incidence was not different between the 2 groups, suggesting that alendronate discontinuation might be reasonable in most patients. This study raises a number of issues.
Delmas PD. Use of Alendronate After 5 Years of Treatment. JAMA. 2007;297(18):1979–1981. doi:10.1001/jama.297.18.1979-c
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.